IP Library Granted Patent US 10,024,817
Granted Patent B2
US 10,024,817 · App. 14/887,291 · Granted Jul 17, 2018

Method for detecting proteases and active infection in biological fluids and tissues

Inventors: Mark R. Wardell (Fort Myers, FL); Kenneth A. Sabacinski (Plantation, FL)
Assignee: PeloGenix, LLC
G01N27/3277C12Q1/005C12Q1/37G01N33/5438
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,024,817
App. No.
14/887,291
Granted
Jul 17, 2018
Kind
B2
Abstract

Electrochemical biosensing devices and methods detect the activity of proteases and active infection in biological samples. The devices and methods utilize distance constraints between a redox reporter and an electrode to create a change in current that is detected. The distance constraints are released when an analyte containing a specified protease or proteases reacts with a protein substrate sequence in the analyte. The particular protease or proteases to be detected can be selected by using biosensors with particular substrate sequences. The devices and methods are not only qualitative, they can be used to quantitatively evaluate protease content in samples.

Claims (44)

1. A method for detecting proteases, which comprises:

providing an electrochemical biosensor, said electrochemical biosensor including:

a biosensor electrode;

a first reagent including:

a lifting structure having a first terminus and a second terminus, said first terminus opposing said second terminus, said first terminus being covalently bonded to said biosensor electrode;

a protease substrate peptide sequence having a first terminus and a second terminus, said first terminus opposing said second terminus, said first terminus being connected to said second terminus of said lifting structure; and

a first binding component being connected to said second terminus of said protease substrate sequence;

a second reagent known as a signaling oligonucleotide including:

a spacer sequence having a first terminus and a second terminus, said first terminus opposing said second terminus, said first terminus being covalently bonded to said biosensor electrode;

a second binding component having a first terminus and a second terminus, said first terminus opposing said second terminus, said first terminus being connected to said second terminus of said spacer sequence, said second binding component being specifically bound to said first binding component on said first reagent; and

a redox reporter being connected to said second terminus of said second binding component;

said lifting structure being connected to said first binding component before said protease substrate sequence is cleaved;

said lifting structure imposing a distance constraint between said redox reporter and said biosensor electrode before said protease substrate sequence is cleaved;

said protease substrate sequence being cleavable by a protease; and

said redox reporter contacting said biosensor electrode when said protease substrate sequence is cleaved;

applying a sample to said electrochemical biosensor; and

detecting an electrical change across said biosensor electrode, wherein the detecting step occurs within fifteen minutes (≤15 min) after the sample is applied to said biosensor electrode.

2. The method according to claim 1 , wherein:

said lifting structure includes a peptide; and

said first binding component includes an oligonucleotide.

3. The method according to claim 1 , wherein:

said lifting structure includes a peptide;

said first binding component of said first reagent is an aptamer-recognition peptide sequence; and

said second binding component of said second reagent is an aptamer sequence.

4. The method according to claim 1 , wherein:

said lifting structure includes a first double-stranded DNA segment;

a first strand of said first double-stranded DNA segment includes a portion of said first reagent;

a second strand of said first double-stranded DNA segment includes a portion of said second reagent;

said first binding component of said first reagent is a first strand of a second double-stranded DNA segment; and

said second binding component of said second reagent is a second strand of said second double-stranded DNA segment.

5. The method according to claim 1 , wherein said protease cleavage sequence is an MMP substrate sequence selected from the group consisting of SEQ ID NOs: 1-36.

6. The method according to claim 1 , wherein said protease cleavage sequence is an NSP substrate sequence selected from the group consisting of SEQ ID NOs: 37-45.

7. The method according to claim 1 , wherein said protease cleavage sequence includes an MMP substrate sequence and an NSP substrate sequence selected from the group consisting of SEQ ID NOs: 46-47.

8. The method according to claim 1 , wherein said lifting structure is a peptide selected from the group consisting of SEQ ID NOs: 48-50.

9. The method according to claim 4 , wherein said first strand of said first double-stranded DNA sequence includes a sequence selected from the group consisting of SEQ ID NOs: 58-59 and said second strand of said second double-stranded DNA sequence selected from the group consisting of SEQ ID NOs: 60-61, respectively (noting that SEQ ID NO: 60 incorporates SEQ ID NO: 63 at the 3′-end and SEQ ID NO: 64 at the 5′-end; and, that SEQ ID NO: 61 incorporates SEQ ID NO: 65 at the 3′-end and SEQ ID NO: 66 at the 5′-end).

10. The method according to claim 1 , wherein said signaling oligonucleotide is selected from the group consisting of SEQ ID NOs: 56-59.

11. The method according to claim 1 , wherein said first reagent and said second reagent are bound to each other via complementary oligonucleotide sequences and are composed of a peptide-oligonucleotide conjugate described in SEQ ID NO: 55, said SEQ ID NO. 55 being constituted by SEQ ID NO: 51 and conjugated to SEQ ID NO: 54, and signaling oligonucleotide SEQ ID NO: 56 (noting that SEQ ID NO: 55 incorporates attachment of SEQ ID NO: 62 at the carboxy-terminus).

12. The method according to claim 1 , wherein said first reagent and said second reagent are bound to each other via complementary oligonucleotide sequences and are composed of a peptide-oligonucleotide conjugate described in SEQ ID NO: 55, said SEQ ID NO. 55 being constituted by conjugating SEQ ID NO: 52 and SEQ ID NO: 54, and signaling oligonucleotide SEQ ID NO: 56 (noting that SEQ ID NO: 55 incorporates attachment of SEQ ID NO: 62 at the carboxy-terminus).

13. The method according to claim 1 , wherein said first reagent and said second reagent are bound to each other via aptamer recognition peptide/aptamer interaction and are composed of an aptamer recognition peptide described in SEQ ID NO: 53 and a signaling oligonucleotide aptamer described in SEQ ID NO: 57.

14. The method according to claim 1 , wherein said first reagent and said second reagent are composed of said oligonucleotide-peptide-oligonucleotide conjugates and are selected from the group consisting of SEQ ID NOs: 60-61 and said signaling oligonucleotides selected from the group consisting of SEQ ID NOs: 58-59, respectively (noting that SEQ ID NO: 60 incorporates SEQ ID NO: 63 at the 3′-end and SEQ ID NO: 64 at the 5′-end; and, that SEQ ID NO: 61 incorporates SEQ ID NO: 65 at the 3′-end and SEQ ID NO: 66 at the 5′-end).

15. The method according to claim 1 , wherein said the redox reporter is methylene blue.

16. The method according to claim 1 , wherein said biosensor electrode is made of a material selected from the group consisting of gold, platinum, carbon, nafion-coated carbon, and polymers thereof.

17. The method according to claim 1 , which further comprises taking said sample from a site selected from the group consisting of a wound, gingival crevice fluid, and bronchoalveolar lavage.

18. The method according to claim 1 , wherein said proteases are active MMP or NSP proteases that indicate abnormally elevated protease levels, and/or an active infection.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2017
From: WARDELL, MARK R.; SABACINSKI, KENNETH A.
To: PELOGENIX, LLC
Reel/Frame 043483/0500 →
Continuity (2)
Provisional Application 62065440 · Oct 17, 2014
Related Publication 20160109401A1 · Apr 21, 2016